Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
KYMR
#901
Kymera Therapeutics, Inc. Common Stock
91.350
0
+1.44%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+1.44%
Monthly Change
+25.93%
6 month change
+54.57%
Year Change
+54.57%
Previous Close
90.050
0
Open
91.380
0
Bid
Ask
Low
91.350
0
High
91.380
0
Volume
150
Markets
US Stock Market
Healthcare
KYMR
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Dividends per share
—
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
—
News
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress
RBC Capital raises Kymera Therapeutics price target on pipeline progress
RBC Capital raises Kymera Therapeutics price target on pipeline
Stifel reiterates Buy rating on Kymera Therapeutics stock at $114
Kymera Q4 2025 slides: pipeline advances despite revenue miss
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
Kymera Therapeutics launches $500 million at-the-market stock offering
Kymera earnings missed by $0.18, revenue fell short of estimates
Kymera Therapeutics CEO Nello Mainolfi sells $2.7 million in shares
Kymera Therapeutics: The More This Biotech Spends, The Higher Its Valuation Rises (KYMR)
Kymera earnings up next as protein degrader rally faces catalyst test